The formation of non-canonical G-quadruplex (G4) DNA structures within KRAS’s core promoter offers a molecular target to decrease gene expression, utilizing a small molecule with promise in cancer cells that harbor aberrant KRAS signaling and in a manner independent of the mutational status. The gene discussed is KRAS; the disease is cancer.